ESC 2022: PACIFIC-STROKE: Dosing of Asundexian in Pts With Non-Cardioembolic Ischemic Stroke

Watch on Radcliffe Cardiology: www.ecrjournal...
Prof Ashkan Shoamanesh (McMaster University, CA) reveals the findings of the PACIFIC-STROKE trial. This multicenter study aims to find the best dose of oral FXIa inhibitor, asundexian (Bayer). 1,808 patients with non-cardioembolic ischaemic stroke were included in this trial and were randomized to receive different doses of asundexian.
Questions:
1. What is the importance of this study?
2. What was the study design and eligibility criteria?
3. What is the mechanism of action and what were the considerations around dosing in this study?
4. What data are you presenting at ESC?
6. What are the next steps?
Recorded onsite at ESC, Barcelona, 2022.
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.